Active	Status	Sponsor type	Region	Phase	Filter
22 Active 2 Inactive 24 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

22 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Valentine, John
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease	Recruiting	4	150	Canada, US	Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara	Takeda	Crohn's Disease	06/27	06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	Recruiting	4	65	Canada, US	Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550	Takeda	Ulcerative Colitis	07/27	07/27
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
DuVall, George
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease	Recruiting	4	150	Canada, US	Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara	Takeda	Crohn's Disease	06/27	06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)	Recruiting	4	65	Canada, US	Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550	Takeda	Ulcerative Colitis	07/27	07/27
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2	Recruiting	3	612	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	3	160	Europe, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	08/24	09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Recruiting	3	778	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Crohn's Disease	11/24	12/26
VICTRIVA, NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	Recruiting	3	396	Canada, US	Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo	Takeda	Crohn's Disease	06/27	08/28
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease	Recruiting	2	268	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Crohn's Disease	09/26	07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	207	Europe, Canada, Japan, US, RoW	TAK-279, Zasocitinib, Placebo	Takeda	Ulcerative Colitis	09/26	08/27
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis	Recruiting	2	140	Europe, Japan, US, RoW	Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo	Eli Lilly and Company	Ulcerative Colitis, Ulcerative Colitis Chronic	12/27	09/28
NCT06109441: Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics	Active, not recruiting	2	30	Canada, US	ALTB-268	AltruBio Inc.	Ulcerative Colitis	04/25	03/26
Guram, Maninder
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP	Active, not recruiting	3	1667	Europe, Canada, Japan, US, RoW	GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)	GlaxoSmithKline, Iqvia Pty Ltd	Asthma	10/25	10/25
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode	Active, not recruiting	N/A	44467	US		Guardant Health, Inc., Premier Research Group plc	Colorectal Cancer	03/24	12/25
Vasudevan, Abhinav
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1	Recruiting	3	612	Europe, Canada, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	03/25	04/25
ABTECT, NCT05535946: - Maintenance	Recruiting	3	1050	Europe, Canada, Japan, US, RoW	ABX464, Obefazimod, Placebo	Abivax S.A.	Ulcerative Colitis	01/26	01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis	Recruiting	3	1063	Europe, Canada, Japan, US, RoW	Mirikizumab, LY3074828	Eli Lilly and Company	Ulcerative Colitis	07/26	12/27